Cue Biopharma, Inc.(CUE)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,543 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in CUE
Events flagged as statistical outliers against CUE's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-08-14
CUE quality score dropped 12 points (27→15) on a new filing
View source filing →
CUE Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Cue Biopharma, Inc. (CUE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CUE at 28.9/100 on a 32-signal composite quality model, placing it at rank #2,543 of 2,962 stocks — the bottom half of the AI-ranked universe. CUE scores in the top quartile across revenue growth (97.8). Areas of concern include balance sheet strength (0.1) and profitability (3.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Cue Biopharma, Inc. reports quarterly revenue of $7.9M, net income of $-153.1M, free cash flow of $-29.0M. Top institutional holders of CUE by reported 13-F value include Bleichroeder, DRIEHAUS CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CUE trades on the Nasdaq exchange and files with the SEC under CIK 1645460. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CUE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cue Biopharma, Inc. directly from SEC EDGAR. Cue Biopharma, Inc.'s 13F Pro composite quality score has ranged between 15 and 30 since 2026, currently 28.9 — an improving long-term trajectory across 30 quarterly and live scoring snapshots.
Revenue
Q2 2026
$7.9M
Net Income
Q2 2026
$-153.1M
Free Cash Flow
Q2 2026
$-29.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+195.7% YoYNet Income
+34.6% YoYOperating Income
+36.0% YoYEPS (Diluted)
+61.1% YoYTotal Assets
+31.1% YoYTotal Debt
Op. Cash Flow
+40.3% YoYFree Cash Flow
+39.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $27.5M +195.7% | $9.3M +69.2% | $5.5M +341.0% | $1.2M -91.7% | $14.9M +373.7% | $3.2M |
| Net Income | $-26.6M +34.6% | $-40.7M +19.8% | $-50.7M +4.3% | $-53.0M -20.0% | $-44.2M +1.4% | $-44.8M |
| Operating Income | $-26.6M +36.0% | $-41.5M +20.4% | $-52.1M +2.0% | $-53.2M -21.8% | $-43.7M +3.0% | $-45.0M |
| EPS (Diluted) | $-0.28 +61.1% | $-0.72 +35.1% | $-1.11 +25.5% | $-1.49 -5.7% | $-1.41 | — |
| Total Assets | $42.2M +31.1% | $32.2M -47.7% | $61.5M -32.6% | $91.3M +9.5% | $83.4M -16.2% | $99.5M |
| Total Debt | — | $37.0K -99.6% | $8.2M -18.5% | $10.1M | $0.00 | — |
| Operating Cash Flow | $-21.7M +40.3% | $-36.3M +9.1% | $-40.0M +4.4% | $-41.8M -7.6% | $-38.8M -19.5% | $-32.5M |
| Free Cash Flow | $-21.9M +39.9% | $-36.4M +8.9% | $-40.0M +4.8% | $-42.0M -5.6% | $-39.8M -20.1% | $-33.1M |
Get alerted when CUE's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Cue Biopharma, Inc. including:
Top Institutional Holders of CUE
Bleichroeder LP
$11.7M370,682 shDRIEHAUS CAPITAL MANAGEMENT LLC
$9.2M292,144 shVANGUARD CAPITAL MANAGEMENT LLC
$5.1M161,700 shIkarian Capital, LLC
$3.3M104,364 shTFG Asset Management GP Ltd
$3.0M93,819 shStemPoint Capital LP
$2.1M66,995 shBlackRock, Inc.
$1.8M57,807 shADAR1 Capital Management, LLC
$1.7M55,193 shLion Point Capital, LP
$1.7M52,928 shSquadron Capital Management LLC
$1.6M50,000 sh
| Fund | Value | Shares |
|---|---|---|
| Bleichroeder LP | $11.7M | 370,682 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | $9.2M | 292,144 |
| VANGUARD CAPITAL MANAGEMENT LLC | $5.1M | 161,700 |
| Ikarian Capital, LLC | $3.3M | 104,364 |
| TFG Asset Management GP Ltd | $3.0M | 93,819 |
| StemPoint Capital LP | $2.1M | 66,995 |
| BlackRock, Inc. | $1.8M | 57,807 |
| ADAR1 Capital Management, LLC | $1.7M | 55,193 |
| Lion Point Capital, LP | $1.7M | 52,928 |
| Squadron Capital Management LLC | $1.6M | 50,000 |
Companies Similar to CUE
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
CG Oncology, Inc.
AGIOS PHARMACEUTICALS, INC.
ASSEMBLY BIOSCIENCES, INC.
Invivyd, Inc.
Viridian Therapeutics, Inc.\DE
BICYCLE THERAPEUTICS PLC
CYTOKINETICS INC
Ovid Therapeutics Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put CUE on your watchlist
Track score changes the day Cue Biopharma, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CUE a good stock to buy?
13F Pro's AI-powered analysis of Cue Biopharma, Inc. (CUE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CUE are available on the CUE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CUE is classified as a small company.
Which hedge funds own CUE?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CUE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cue Biopharma, Inc.'s investment landscape.